| Trial ID: | L2159 |
| Source ID: | NCT05556291
|
| Associated Drug: |
Combinations Of Oral Blood Glucose Lowering Drugs
|
| Title: |
Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study
|
| Acronym: |
CEASE
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Efficacy|Safety|Tolerability
|
| Interventions: |
DRUG: Combinations of Oral Blood Glucose Lowering Drugs
|
| Outcome Measures: |
Primary: Change from baseline in HbA1c% to the last-observation., Efficacy, up to 24 weeks|Change from baseline in fasting plasma glucose to the last- observation on treatment, Efficacy, 24 weeks|Change from baseline in bodyweight & BMI, Efficacy, till 24 weeks | Secondary: Frequency of adverse events during the course of study follow-up, Safety, 24 weeks|Frequency of serious adverse events, Safety, up to 24 weeks|Percentage of patients who discontinued investigational drug due to adverse events, Tolerability, up to 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Getz Pharma | Collaborators: Primary Care Diabetes Association, Pakistan
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
190
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-12-01
|
| Completion Date: |
2024-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-20
|
| Locations: |
Doctor's Plaza, Karachi, Sindh, 75330, Pakistan|Khan's Clinic, Karachi, Sindh, 75330, Pakistan|PECHS, Karachi, Sindh, 75330, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT05556291
|
